Kyorin Pharmaceutical Co (TSE:4569) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
69 GF Score
Price 円1,128.00
GF Value 円1,576.61
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kyorin Pharmaceutical Co  (TSE:4569) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Related Terms


Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.77 0.79 0.63 0.68

Kyorin Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.62 0.64 0.68 0.48

TSE:4569 vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


TSE:4569
69GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyorin Pharmaceutical Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kyorin Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kyorin Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2442.352/113.6000*113.6000
=2,442.352

Current CPI (Jun. 2026) = 113.6000.

Kyorin Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 2,093.697 98.000 2,426.979
201612 2,109.093 98.400 2,434.888
201703 2,146.810 98.100 2,486.010
201706 2,154.290 98.500 2,484.542
201709 2,138.986 98.800 2,459.401
201712 2,199.367 99.400 2,513.562
201803 2,214.088 99.200 2,535.488
201806 2,178.456 99.200 2,494.683
201809 2,228.798 99.900 2,534.449
201812 2,116.419 99.700 2,411.486
201903 2,154.019 99.700 2,454.329
201906 2,102.158 99.800 2,392.837
201909 2,086.300 100.100 2,367.669
201912 2,143.610 100.500 2,423.026
202003 2,142.024 100.300 2,426.061
202006 2,146.513 99.900 2,440.880
202009 2,153.498 99.900 2,448.823
202012 2,136.956 99.300 2,444.695
202103 2,175.473 99.900 2,473.811
202106 2,113.014 99.500 2,412.446
202109 2,127.798 100.100 2,414.764
202112 2,143.958 100.100 2,433.103
202203 2,172.824 101.100 2,441.472
202206 2,181.676 101.800 2,434.562
202209 2,176.729 103.100 2,398.413
202212 2,212.555 104.100 2,414.469
202303 2,189.396 104.400 2,382.331
202306 2,177.044 105.200 2,350.876
202309 2,197.188 106.200 2,350.288
202312 2,203.283 106.800 2,343.567
202403 2,275.673 107.200 2,411.534
202406 2,263.710 108.200 2,376.686
202409 2,263.349 108.900 2,361.033
202412 2,264.151 110.700 2,323.465
202503 2,372.281 111.100 2,425.663
202506 2,369.987 111.700 2,410.300
202509 2,375.005 112.000 2,408.934
202512 2,417.367 113.000 2,430.203
202603 2,479.257 112.700 2,499.056
202606 2,442.352 113.600 2,442.352

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,128.00 is trading 28.5% below its estimated GF Value™ of 円1,576.61. GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4569:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: 円1,576.61 vs. price of 円1,128.00 (28.5% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
69GF Score

Get the complete analysis for TSE:4569

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,128.00
Price
円1,576.61
GF Value